Bio-Rad Laboratories, Inc.
$386.12-0.4%YTD+9.7%1Y+32.8%
Mentions · last 7 days
370+8%
Price updated 6h ago·X counts updated 7d ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $BIO, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Devices sits in its cycle right now — and what that implies for $BIO.
Medical - Devices
Elective procedure volume recovery and aging-demographic demand are the structural drivers; robotic surgery adoption (ISRG) and GLP-1-driven procedure mix shifts are the near-term dynamics. Hospital capex cycles determine device upgrade timing — CapEx returning after COVID deferral.
What this means for $BIO
Partial — upstream oil & gas exposure ties to commodity price cycle; Bio-Rad Laboratories, Inc.
Industry benchmark
25-name peer basket
+7.6%YTD
+24.5%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
47.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
2.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
9.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
4.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
3.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
2.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
51.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$2.62$1.75+49.7%
Q1 2026Apr 30, 2026$1.89$1.97-4.1%
Q4 2025Feb 12, 2026$2.51$2.57-2.3%
Q3 2025Oct 29, 2025$2.26$2.30-1.7%
Next earningsThu, Oct 29·consensus EPS $2.23
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$592.1M+1.1%52.3%5.8%$-19.55$78.1M
Q4 FY25$693.2M+3.9%49.8%8.9%$26.69$119.1M
Q3 FY25$653.0M+0.5%52.6%10.2%$-12.70$89.2M
Q2 FY25$651.6M+2.1%53.0%11.8%$11.67$70.8M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$2.6B$2.5B – $2.6B$9.04$8.75 – $9.233
FY27$2.7B$2.6B – $2.7B$9.96$9.65 – $10.184
FY28$2.8B$2.6B – $2.8B$11.15$10.79 – $11.383
FY29$2.8B$2.7B – $2.9B$12.17$11.78 – $12.432
FY30$2.9B$2.8B – $2.9B$13.76$13.32 – $14.051
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.94%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+17.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+28.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 17.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.055-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KRestructuring / exit costsAug 48-K — Item 2.02: Earnings release · Item 2.05: Restructuring / exit costs · Item 7.01: Press release / Reg FD
AI summary
8-KPress release / Reg FDApr 308-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary
8-KOfficer or director changeApr 248-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary
+ 7 other (2 10-Qs · 1 SD · 1 S-8 · 1 13G) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Bio-Rad to Participate in Fireside Chat During Wells Fargo's 21st Annual Healthcare ConferenceIs Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?BIO-key's Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ETFirst Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO
More in Medical - Devices
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $BIO on X in the last 7 days.